Numbers of samples analyzed at diagnosis and during follow-up
. | Diagnosis . | 2-3 wk, 1st induction . | 4-8 wk, 2nd induction . | 3-4 mo, consolidation . | 5-6 mo . | 7-9 mo . | 10-12 mo . | 13-18 mo . | 19-24 mo . | Later . | Total . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AML1-ETO | 106 | 25 | 18 | 18 | 14 | 12 | 6 | 7 | 2 | 3 | 211 |
| CBFB-MYH11 | 122 | 24 | 23 | 27 | 20 | 22 | 20 | 18 | 10 | 11 | 303 |
| PML-RARA | 121 | 27 | 44 | 41 | 27 | 19 | 19 | 18 | 11 | 18 | 345 |
| Total | 349 | 76 | 85 | 86 | 61 | 53 | 45 | 43 | 23 | 31 | 859 |
. | Diagnosis . | 2-3 wk, 1st induction . | 4-8 wk, 2nd induction . | 3-4 mo, consolidation . | 5-6 mo . | 7-9 mo . | 10-12 mo . | 13-18 mo . | 19-24 mo . | Later . | Total . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AML1-ETO | 106 | 25 | 18 | 18 | 14 | 12 | 6 | 7 | 2 | 3 | 211 |
| CBFB-MYH11 | 122 | 24 | 23 | 27 | 20 | 22 | 20 | 18 | 10 | 11 | 303 |
| PML-RARA | 121 | 27 | 44 | 41 | 27 | 19 | 19 | 18 | 11 | 18 | 345 |
| Total | 349 | 76 | 85 | 86 | 61 | 53 | 45 | 43 | 23 | 31 | 859 |